Altimmune, Inc.
NASDAQ:ALTBiotechnology
+$0.08 today
- Market cap
- $270.48M
- Beta
- 0.23
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$0.73
Volume 4.69M
Average 3.81M
ALT Total Liabilities
Everything the company owes to creditors and other parties.
Altimmune, Inc.NASDAQ: ALT
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 242.0% from a year ago
Total liabilities stood at $51.64M at the end of Q1 FY2026, up 242.0% from a year earlier and down 6.2% from the prior quarter. Over 3 fiscal years it compounded at +36.5% a year.
Context
- Total liabilities amounted to 15.4% of total assets at the end of Q1 FY2026, up 5.8 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +242.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 55.04M USD
- Year-over-year change
- +248.4%
- 4-year CAGR
- +29.2%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 55.04M | +248.4% |
| FY2024 | 2024-12-31 | 15.8M | -4.5% |
| FY2023 | 2023-12-31 | 16.54M | -23.5% |
| FY2022 | 2022-12-31 | 21.64M | +9.7% |
| FY2021 | 2021-12-31 | 19.73M | — |
Total Liabilities vs competitors
How ALT compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +242.0% is the highest of 9, against a peer median of -16.5%.
- Total liabilities amounts to 15.4% of total assets for ALT, versus a peer median of 31.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | €277.91M EUR | +23.2% | +57.9% | 111.7% | |
| Mar 2026 | $212.82M USD | -19.4% | -31.0% | 20.8% | |
| Mar 2026 | $198.12M USD | -13.7% | +53.9% | 63.0% | |
| Jun 2026 | $71.01M USD | +60.1% | -31.8% | 5.0% | |
| Mar 2026 | $51.64M USD | +242.0% | +36.5% | 15.4% | |
| Mar 2026 | $36.9M USD | -48.7% | +38.5% | 15.7% | |
| Mar 2026 | $27.67M USD | +5.1% | +11.8% | 59.6% | |
| Mar 2026 | $16.99M USD | -55.1% | -32.5% | 6.1% | |
| Mar 2026 | $933K USD | -64.3% | +21.5% | 42.8% | |
| Peer median (excluding ALT) | — | -16.5% | +16.7% | 31.8% | |
Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 190.3M | 111.1M | 135.12M | 36.93M | 43.76M |
| Short-term Investments | 0 | 73.78M | 62.7M | 94.97M | 229.7M |
| Net Receivables | 5.84M | 2.54M | 4.85M | 3.12M | 1.74M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 33.31K | 5.39M | 6.96M | 2.25M | 3M |
| Total Current Assets | 204.13M | 192.81M | 209.63M | 137.25M | 278.19M |
| Property, Plant & Equipment (Net) | 1.45M | 1.08M | 651K | 413K | 312K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 12.42M | 12.42M | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 872K | 615K | 363K | 1.64M | 1.43M |
| Total Non-current Assets | 14.74M | 14.12M | 1.01M | 2.05M | 1.74M |
| Total Assets | 218.87M | 206.93M | 210.64M | 139.31M | 279.93M |
| Account Payables | 2.03M | 4.8M | 2.07M | 211K | 2.72M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 1.17M | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 6.09M | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 18.28M | 17.05M | 12.14M | 10.47M | 15M |
| Long-term Debt | 0 | 0 | 0 | 0 | 34.29M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 160K |
| Other Non-current Liabilities | 330K | 3.91M | 4.22M | 3.93M | 4.45M |
| Total Non-current Liabilities | 1.45M | 4.58M | 4.4M | 5.33M | 40.04M |
| Total Liabilities | 19.73M | 21.64M | 16.54M | 15.8M | 55.04M |
| Common Stock | 4K | 5K | 7K | 7K | 11K |
| Retained Earnings | (293.17M) | (377.88M) | (466.33M) | (561.39M) | (649.48M) |
| Accumulated OCI | (5.04M) | (5.23M) | (5M) | (4.97M) | (4.93M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 199.14M | 185.29M | 194.1M | 123.51M | 224.89M |
| Total Debt | 1.54M | 1.12M | 671K | 1.68M | 35.69M |
| Net Debt | (188.77M) | (109.97M) | (134.45M) | (35.25M) | (8.07M) |
Altimmune, Inc.
NASDAQ:ALT
Intrinsic Alpha fair value
Locked
Current Price
$1.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.